title: Cisplatin therapy in 41 dogs with malignant tumors.
abstract: Forty-one dogs with a variety of histopathologically diagnosed, measurable tumors were treated with cisplatin (cis-diamminedichloroplatinum, Platinol, Bristol Laboratories, Syracuse, NY 13221-4755) as a single agent at a dosage of 60 mg/m2 given intravenously at 3-week intervals. In an attempt to avoid renal toxicity of cisplatin, saline diuresis was induced and maintained for 4 hours before and 2 hours following cisplatin administration. The dogs received one to ten doses of cisplatin. To determine response to therapy and to monitor toxicity of the drug, the dogs were evaluated with physical examinations including tumor measurements, radiography, complete blood counts, platelet counts, urinalyses, serum urea nitrogen concentrations, and serum creatinine concentrations. An overall response rate of 19% was observed. Complete remission occurred in one of 11 dogs with squamous cell carcinomas and one of one dog with a mediastinal undifferentiated carcinoma. Partial remissions were documented in one of 11 dogs with squamous cell carcinomas, two of three dogs with metastatic osteosarcomas, one of three dogs with nasal adenocarcinomas, and one of one dog with a thyroid adenocarcinoma. Toxic side effects were primarily gastrointestinal in nature, with vomiting occurring 1-6 hours after cisplatin administration in 27 of 41 dogs. Severe anorexia occurred in three dogs, and hemorrhagic diarrhea was observed in one dog. One dog developed grand mal seizures and died 3 hours following therapy. Granulocytopenia was documented in six dogs, and thrombocytopenia was observed in four dogs. One dog showed an increase in serum urea nitrogen and creatinine concentrations, but this patient had known pre-existing renal disease.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Purdue Comparative Oncology Program, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-7403.
authors.forename: D W
authors.initials: DW
authors.lastname: Knapp
authors.forename: R C
authors.initials: RC
authors.lastname: Richardson
authors.forename: P L
authors.initials: PL
authors.lastname: Bonney
authors.forename: K
authors.initials: K
authors.lastname: Hahn
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000662:veterinary; D000818:Animals; D002277:Carcinoma / Q000188:drug therapy / Q000662:veterinary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000662:veterinary; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004285:Dogs; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000662:veterinary; D014839:Vomiting / Q000662:veterinary
chemical_list: D002945:Cisplatin